A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 TrialDominick J. Angiolillo, Mark B. Effron, J J Badimón et al.|European Heart Journal|2011Cited by 182
Increased Platelet Inhibition After Switching From Maintenance Clopidogrel to Prasugrel in Patients With Acute Coronary SyndromesDominick J. Angiolillo, Mark B. Effron, Jorge F. Saucedo et al.|Journal of the American College of Cardiology|2010Cited by 168
The Influence of Smoking Status on the Pharmacokinetics and Pharmacodynamics of Clopidogrel and PrasugrelPaul A. Gurbel, Brian Baker, Kevin P. Bliden et al.|Journal of the American College of Cardiology|2013Cited by 139
Comparison of Prasugel With Clopidogrel on Platelet Function in Coronary Artery Disease Patients With Type 2 Diabetes Mellitus - Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)Dominick J. Angiolillo, Mark B. Effron, Juan J. Badimon et al.|Queensland's institutional digital repository (The University of Queensland)|2009Cited by 3
TCT-54 The Influence of Smoking Status On The Pharmacodynamics of Prasugrel and Clopidogrel:The PARADOX StudyPaul A. Gurbel, Brian Baker, Kevin P. Bliden et al.|Journal of the American College of Cardiology|2012Cited by 3